Mundipharma offers new opportunities in the treatment of lymphomas.

Lymphomas are diseases of the blood system that are serious and potentially deadly. Peripheral T-cell lymphomas are conditions that, although rare, are of poor prognosis. Mundipharma has in its portfolio the first product approved by the American Regulatory Agency (FDA) for the treatment of this disease offering a therapeutic option.